Frazier O H, Kadipasaoglu K A, Radovancevic B, Cihan H B, March R J, Mirhoseini M, Cooley D A
Division of Cardiopulmonary Transplantation, Cullen Cardiovascular Research Laboratories, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston 77225-0345, USA.
Ann Thorac Surg. 1998 Apr;65(4):1138-41. doi: 10.1016/s0003-4975(98)00022-8.
We used transmyocardial laser revascularization to treat accelerated cardiac allograft atherosclerosis in 2 patients. One patient received transmyocardial laser revascularization as sole therapy, the other as an adjunct to coronary artery bypass grafting. The systolic function improved in both patients, although the patient who had adjunctive transmyocardial laser revascularization died of systemic infection and renal failure on postoperative day 55. The second patient is alive and well 1 1/2 years after the laser procedure. We discuss 4 other patients who received transmyocardial laser revascularization treatment elsewhere in the United States. Transmyocardial laser revascularization has the potential to become important in the treatment of transplant atherosclerosis. Randomized clinical trials are warranted to assess the efficacy of transmyocardial laser revascularization in this setting.
我们使用经心肌激光血运重建术治疗了2例心脏移植加速性动脉粥样硬化患者。1例患者接受经心肌激光血运重建术作为唯一治疗方法，另1例作为冠状动脉旁路移植术的辅助治疗。2例患者的收缩功能均有改善，尽管接受辅助经心肌激光血运重建术的患者在术后第55天死于全身感染和肾衰竭。第2例患者在激光手术后1年半仍然存活且状况良好。我们还讨论了在美国其他地方接受经心肌激光血运重建术治疗的另外4例患者。经心肌激光血运重建术在移植动脉粥样硬化的治疗中有可能变得重要。有必要进行随机临床试验来评估经心肌激光血运重建术在此种情况下的疗效。
